Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

598
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
598
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

737
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
737
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.1K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

588
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
588

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping.

Discover oncology·2026
Same author

Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based <i>MET</i> Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer.

Lung Cancer (Auckland, N.Z.)·2026
Same author

Abnormal cortical hierarchy revealed by gradient dysfunction in patients with definite amyotrophic lateral sclerosis.

Brain research bulletin·2026
Same author

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Nature medicine·2026
Same author

Impairment of brain short association fibers across clinical stages in amyotrophic lateral sclerosis: a new biomarker mirroring disease progression.

BMC medicine·2026
Same author

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Nature communications·2026

Related Experiment Video

Updated: Feb 6, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer

Quan-Quan Tan1, Yu-Qing Chen2, Yu-Er Gao3

  • 1Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), southern Medical University, Guangzhou, China.

Cancer Medicine
|February 4, 2026
PubMed
Summary

Progression patterns after crizotinib treatment for ROS1-rearranged NSCLC significantly impact survival. Understanding these modes, such as dramatic versus gradual/local progression, can guide future treatment decisions.

Keywords:
NSCLCROS1clinical progression modesurvival benefits

More Related Videos

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.9K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K

Related Experiment Videos

Last Updated: Feb 6, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.9K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K

Area of Science:

  • Oncology
  • Medical Genetics
  • Pharmacology

Background:

  • Crizotinib is a standard first-line therapy for ROS1-rearranged non-small cell lung cancer (NSCLC).
  • Limited data exist on clinical progression patterns and subsequent treatment strategies following crizotinib failure in this patient population.

Purpose of the Study:

  • To analyze clinical progression modes in ROS1-rearranged NSCLC patients after crizotinib treatment.
  • To investigate survival outcomes and potential resistance mechanisms associated with different progression patterns.
  • To inform subsequent treatment strategies based on progression modes.

Main Methods:

  • Twenty-eight patients with ROS1-rearranged NSCLC were retrospectively analyzed.
  • Patients were categorized into dramatic or gradual/local progression groups based on clinical data.
  • Clinical characteristics, survival outcomes (progression-free survival, overall survival), and resistance mechanisms were evaluated.

Main Results:

  • Dramatic progression showed significantly shorter median progression-free survival (8.0 months) and overall survival (14.2 months) compared to gradual/local progression (22.0 and 90.3 months, respectively).
  • In dramatic progression, subsequent treatments varied in efficacy, with significant differences in post-progression survival and overall survival across chemotherapy, targeted therapy, and best supportive care.
  • ROS1 kinase domain mutations were prevalent in dramatic progression, whereas bypass and downstream pathway activation characterized gradual/local progression.

Conclusions:

  • Progression modes in ROS1-rearranged NSCLC after crizotinib treatment are predictive of survival outcomes.
  • Identifying progression patterns can help tailor subsequent treatment strategies for improved patient management.